Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Takemura K, Lemelin A, Ernst M, Wells J, Saliby R, El Zarif T, Labaki C, Basappa N, Szabados B, Powles T, Davis I, Wood L, Lalani A, McKay R, Lee J, Meza L, Pal S, Donskov F, Yuasa T, Beuselinck B, Gebrael G, Agarwal N, Choueiri T, Heng D. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology 2024, 86: 488-492. PMID: 38290965, DOI: 10.1016/j.eururo.2024.01.006.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumBrain metastasesRenal cell carcinomaStereotactic radiotherapyOverall survivalSystemic therapyCell carcinomaAssociated with longer median overall survivalAssociated with longer overall survivalInitiation of systemic therapyLonger median overall survivalAssociated with longer OSTyrosine kinase inhibitor monotherapyAssociated with better prognosisIO-based regimensMedian overall survivalWhole-brain radiotherapyFirst-line therapyAdvanced kidney cancerLonger overall survivalOutcomes of patientsGroup of patientsCombination immunotherapyLonger OSInhibitor monotherapy